Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 and Cetuximab in KRAS G12C Mutated Advanced GI Cancers
NCT05194995Phase 2Active, not recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glecirasib in colorectal cancer (CRC), small intestine cancer and appendiceal cancer (3 arms), sponsored by Allist Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 3 weeks and Overall Response Rate up to 4 years. Started Feb 2022; status: active, not recruiting.
02
Drugs
glecirasib
03
Conditions
colorectal cancer (CRC)small intestine cancerappendiceal cancer
Beyond the preview
Go deeper on NCT05194995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194995.